Clinical Investigator Financial Interest Inquiries May Be Costly For Industry
This article was originally published in The Tan Sheet
Executive Summary
Clinical trial sponsors face "prohibitive" costs in developing internal mechanisms to verify clinical investigators' financial interests in the sponsor company, R.W. Johnson's Janice Little said at the Drug Information Association recent annual meeting in Baltimore.